REGNNASDAQHealthcare

REGENERON PHARMACEUTICALS INC

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$904.35

+0.16%

Alpha Vantage · 11/6/2026

Industry: BiotechnologyCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze REGN free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

+22.3%

3 months

+12.1%

6 months

+26.8%

1 year

+40.5%

Year to date

+17.6%

52-week range

$599.96 – $973.36

Fundamental snapshot

Latest reported period: Sep 30, 2026

Sharadar reported data

Market cap

$93.55B

P/E

19.4

P/B

2.8

P/S

5.5

Revenue

$16.9B

Net income

$4.82B

Diluted EPS

45.3

Gross margin

85.80%

Net margin

28.50%

Return on equity

15.10%

Total debt

$2.71B

Cash

$3.66B

Free cash flow

$3.83B

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 30, 2026	$5.12B	$1.95B	88.80%	38.10%	$1.48B
Jun 30, 2026	$4.29B	$1.3B	86.60%	30.20%	$572.8M
Mar 31, 2026	$3.61B	$727.2M	81.40%	20.20%	$848.3M
Dec 31, 2025	$3.88B	$844.6M	84.90%	21.70%	$922M
Sep 30, 2025	$3.75B	$1.46B	86.10%	38.90%	$1.42B
Jun 30, 2025	$3.68B	$1.39B	85.60%	37.90%	$925.4M
Mar 31, 2025	$3.03B	$808.7M	84.70%	26.70%	$815.8M
Dec 31, 2024	$3.79B	$917.7M	85.10%	24.20%	$1.06B

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent REGN news

All market news

Simply Wall St·Nov 4, 202674 signal

How Investors May Respond To Regeneron Pharmaceuticals (REGN) Earnings Beat

Regeneron Pharmaceuticals reported strong third-quarter 2026 results with US$5.1 billion in revenue and US$1.95 billion in net income, exceeding expectations. The company also affirmed its quarterly dividend and continued share buybacks, while expanding its BARDA agreement for Ebola treatment and presenting positive data for Libtayo in skin cancer. These results reinforce Regeneron's earnings engine, with a focus on late-stage pipeline execution and competition in eye care, and analysts anticipate continued revenue and earnings growth through 2029.

Original source